Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: (WFRF:(Strand Sven Erik)) > (2020-2024) > Hematological Toxic...

Details
MARC

Kristiansson, AmandaLund University,Lunds universitet,Antioxidationsmedicin,Forskargrupper vid Lunds universitet,Neonatalogi,Antioxidation medicine,Lund University Research Groups,Neonatology (author)

Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617

Article/chapterEnglish2022

Publisher, publication year, extent ...

2022-03-28
MDPI AG,2022

Numbers

LIBRIS-ID:oai:lup.lub.lu.se:c31df9ad-1b38-4cd1-8e2f-a4b7051301c1
https://lup.lub.lu.se/record/c31df9ad-1b38-4cd1-8e2f-a4b7051301c1URI
https://doi.org/10.3390/pharmaceutics14040731DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:art swepub-publicationtype
Subject category:ref swepub-contenttype

Notes

Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., 177Lu-PSMA-617, has been effective in reducing tumor burden and prolonging survival in mCRPC. However, it is not a curative method with kidney and bone marrow toxicity limiting the activity given to patients. Previous preclinical models have reported transient hematotoxicity for up to 120 MBq. This activity may still be too low to investigate the effect on renal function since it corresponds to an absorbed dose below 10 Gy, whereas the kidneys in a clinical setting usually receive an absorbed dose more than double. Here we investigated the hematotoxicity and recovery after administered activities of 120, 160, and 200 MBq in a 177Lu-PSMA-617 BALB/cAnNRj mouse model. The animals had an initial drop in white blood cells (WBC) starting 4 days post injection, which recovered after 21 days. The effect on red blood cells (RBC) and platelets was detected later; 17 days post-injection levels decreased compared to the control group. The reduction was restored again 32 days post injection. No correlation between injected activity and hematotoxicity was found. Our results suggest that activities up to 200 MBq of 177Lu-PSMA-617 give transient hematotoxicity from which animals recover within a month and no radiation-related deaths. Injecting these high activities could allow animal studies with increased clinical relevance when studying renal toxicity in animal models.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

Vilhelmsson Timmermand, OskarLund University,Lunds universitet,Forskningsgruppen för Systemisk strålterapi,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Systemic Radiation Therapy Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)immu-orv (author)
Altai, MohamedLund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Systemisk strålterapi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Systemic radiation therapy,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)mo8753al (author)
Strand, JoannaLund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Systemisk strålterapi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Systemic radiation therapy,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)jo5371st (author)
Strand, Sven-ErikLund University,Lunds universitet,Forskningsgruppen för Systemisk strålterapi,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Systemic Radiation Therapy Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)rafy-ses (author)
Åkerström, BoLund University,Lunds universitet,Antioxidationsmedicin,Forskargrupper vid Lunds universitet,Antioxidation medicine,Lund University Research Groups(Swepub:lu)medk-bak (author)
Örbom, AndersLund University,Lunds universitet,Forskningsgruppen för Systemisk strålterapi,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Systemic Radiation Therapy Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)med-aom (author)
AntioxidationsmedicinForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

In:Pharmaceutics: MDPI AG14:41999-4923

Internet link

Find in a library

Pharmaceutics (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Kristiansson, Am ...; Vilhelmsson Timm ...; Altai, Mohamed; Strand, Joanna; Strand, Sven-Eri ...; Åkerström, Bo; show more...; Örbom, Anders; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Radiology Nuclea ...

Articles in the publication: Pharmaceutics

By the university: Lund University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se